As a result, CAR-T cell therapy represents a viable approach for achieving sustained B-cell depletion, highlighting the significance of CD19-targeting CAR-T cells as a valuable therapeutic option for managing SLE. This evidence concerns the gene CD19 and systemic lupus erythematosus.